Latest News
Keep up to date with the latest news and announcements from Theragnostics
Theragnostics strengthens leadership team with two key appointments
November 13, 2019GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer
October 9, 2019Theragnostics Reports Positive Clinical Trial
Results from Prostate Cancer Study
October 2, 2019Theragnostics will be @ EANM ’19 – Booth #4
September 30, 2019THERAGNOSTICS SIGNS AGREEMENT
WITH ASTRAZENECA
September 5, 2019Theragnostics CEO Greg Mullen presenting at Targeted Radiopharmaceuticals Summit
June 12, 2019Is it June already?! – Meet us @ SNMMI ’19
June 6, 2019Theragnostics Ltd Expands Oncology Portfolio with Licensing of radioPARP Inhibitor
February 28, 2019Theragnostics will be at the Theranostics World Congress 2019
February 20, 2019News Archive
Theragnostics strengthens leadership team with two key appointments
November 13, 2019GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer
October 9, 2019Theragnostics Reports Positive Clinical Trial
Results from Prostate Cancer Study
October 2, 2019Theragnostics will be @ EANM ’19 – Booth #4
September 30, 2019THERAGNOSTICS SIGNS AGREEMENT
WITH ASTRAZENECA
September 5, 2019Theragnostics CEO Greg Mullen presenting at Targeted Radiopharmaceuticals Summit
June 12, 2019Is it June already?! – Meet us @ SNMMI ’19
June 6, 2019Theragnostics Ltd Expands Oncology Portfolio with Licensing of radioPARP Inhibitor
February 28, 2019News Archive